Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cytosorbents (CTSO) Equity Ratio (2016 - 2026)

Cytosorbents filings provide 16 years of Equity Ratio readings, the most recent being 0.13 for Q4 2025.

  • On a quarterly basis, Equity Ratio fell 43.02% to 0.13 in Q4 2025 year-over-year; TTM through Dec 2025 was 0.13, a 43.02% decrease, with the full-year FY2025 number at 0.13, down 43.02% from a year prior.
  • Equity Ratio hit 0.13 in Q4 2025 for Cytosorbents, down from 0.2 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.88 in Q1 2021 to a low of 0.13 in Q4 2025.
  • Median Equity Ratio over the past 5 years was 0.45 (2023), compared with a mean of 0.48.
  • Biggest five-year swings in Equity Ratio: soared 83.26% in 2021 and later tumbled 47.12% in 2024.
  • Cytosorbents' Equity Ratio stood at 0.7 in 2021, then fell by 19.97% to 0.56 in 2022, then fell by 20.75% to 0.44 in 2023, then tumbled by 47.12% to 0.23 in 2024, then crashed by 43.02% to 0.13 in 2025.
  • The last three reported values for Equity Ratio were 0.13 (Q4 2025), 0.2 (Q3 2025), and 0.24 (Q2 2025) per Business Quant data.